Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: LOBEF )

0.0290 UNCHANGED
Streaming Delayed Price Updated: 2:35 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0290
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0290
Today's Range 0.0290 - 0.0290
52wk Range 0.0081 - 0.2686
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!
By Richard Dal Monte 
Via TheNewswire.com
Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!
As early as the 1950s, scientists were researching the possible therapeutic benefits of psychedelics such as LSD and psilocybin mushrooms. 
Via Benzinga

Performance

YTD
-7.64%
-7.64%
1 Month
+11.54%
+11.54%
3 Month
N/A
N/A
6 Month
-60.81%
-60.81%
1 Year
+28.89%
+28.89%

More News

Read More
Chronic Cluster Headaches, Next Target For This Non-Hallucinogenic Psychedelic
Via Benzinga
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
Via FinancialNewsMedia
Topics Economy
Exposures Supply Chain
Mass-Scale Psilocin Clinical Supplies Are Ready For Upcoming Trials
Via Benzinga
New Share Consolidation of Lobe Sciences Ltd., Here's What Changes
Via Benzinga
Lobe Sciences, Ltd. Enters Collaborative Clinical Research Agreement with Integrative Headache Medicine of New York to Study the Effects of L-130 in the Treatment of Chronic Cluster Headache
Via FinancialNewsMedia
Exposures Product Safety
Lobe Sciences Ltd (LOBEF) increases its portfolio with several new chemical entities (NCEs)
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Trippy Trading: Top Psychedelic Stocks For 2023
Via TheNewswire.com
Topics Cannabis
Exposures Cannabis
Lobe Sciences Announces Incorporation of Australian Subsidiary
Via Newsfile
Lobe Sciences Announces Closing of Private Placement
Via Newsfile
Psychedelics Funding At Its Best: $1.5 M Destined To Psilocybin Clinical Trials In Australia
Via Benzinga
Lobe Sciences and Cantheon Capital Enter into Exclusive Investment Agreement to Fund $1.5M USD Toward Clinical Trials in Australia
Via Newsfile
Topics Cannabis
Exposures Cannabis
This Psychedelic Company Just Signed An Exclusive Deal For Psilocin Clinical Trials In Australia
Via Benzinga
Two Psychedelic Companies File Patent Applications For Psilocybin And MDMA Analogues, Here's What Could Change
Via Benzinga
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
Via Benzinga
Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) Featured in Coverage of Planet MicroCap’s Virtual Investor Conference
Via Investor Brand Network
Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) Featured in Coverage of Investor Summit Group’s Q1 Virtual Event
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.